| Item Type | Name |
|
Concept
|
Recurrence
|
|
Concept
|
Neoplasm Recurrence, Local
|
|
Academic Article
|
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
|
|
Academic Article
|
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
|
|
Academic Article
|
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
|
|
Academic Article
|
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
|
|
Academic Article
|
Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
|
|
Academic Article
|
Novel therapies for relapsed/refractory multiple myeloma: how can we improve on "salvage" therapy?--introduction.
|
|
Academic Article
|
Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.
|
|
Academic Article
|
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
|
|
Academic Article
|
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
|
|
Academic Article
|
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
|
|
Academic Article
|
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
|
|
Academic Article
|
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
|
|
Academic Article
|
Evolving strategies in the initial treatment of multiple myeloma.
|
|
Academic Article
|
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
|
|
Academic Article
|
Introduction: recent advances in the understanding and management of multiple myeloma.
|
|
Academic Article
|
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
|
|
Academic Article
|
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
|
|
Academic Article
|
Current strategies for treatment of relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
|
|
Academic Article
|
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
|
|
Academic Article
|
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
|
|
Academic Article
|
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
|
|
Academic Article
|
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
|
|
Academic Article
|
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
|
|
Academic Article
|
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
|
|
Academic Article
|
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
|
|
Academic Article
|
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
|
|
Academic Article
|
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
|
|
Academic Article
|
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
|
|
Academic Article
|
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
|
|
Academic Article
|
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
|
|
Academic Article
|
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
|
|
Academic Article
|
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
|
|
Academic Article
|
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
|
|
Academic Article
|
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
|
|
Academic Article
|
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.
|
|
Academic Article
|
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
|
|
Academic Article
|
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
|
|
Academic Article
|
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
|